EXOPHARM – HALF YEAR REPORT
Exopharm – Half Year Financial Report ended 31 December 2021
EX1 – QUARTERLY ACTIVITIES REPORT
Quarterly Activities Report and Appendix 4C • US Patent granted for Exopharm’s LEAP™ technology supports partnering • Exopharm and… Read more
Exopharm sign “Master Collaborative Services Agreement” with Astellas Institute for Regenerative Medicine (AIRM),
Highlights from the Announcement: Astellas Institute of Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20… Read more
Exopharm Gains US Patent for LEAP™ Commercial Exosome Production Technology
The US Patent and Trademark Office has granted Exopharm its first US patent US 112022805 “Methods And Compositions For Purification… Read more
Exopharm to Present at Key Exosome Industry Event
Exopharm Limited (ASX:EX1), a clinical-stage, global leader in exosome medicines, announces that Chief Commercial Officer and Deputy CEO, Dr Chris… Read more
Exosomes – Industry News
Exosomes continue to make news and build momentum in the pharmaceutical industry. On Tuesday this week Swiss based Lonza Group… Read more
Exopharm Quarterly Activities Report and Appendix 4C
• Second commercial collaboration for Exopharm’s unique LEAP technologies underway with global manufacturer Showa Denko • Exopharm’s LEAP patent application… Read more
Exopharm Appointment of Company Secretary
Exopharm Limited (ASX: EX1) (“Exopharm” or the “Company”) announces the appointment of Mr David Franks as Company Secretary.
Exopharm’s LEAP Technology – Further Step Towards US Patent
• The USPTO has issued a ‘Notice of Allowance Mailed’ note for the Company’s LEAP patent application (Application 17/147,033) •… Read more